In their study titled "Electroporation-mediated Metformin for effective anticancer treatment of triple-negative breast cancer cells," authors Praveen Sahu, Ignacio G. Camarillo, Pragatheiswar Giri, and Raji Sundararajan explored the potential of Metformin as a treatment for triple negative breast cancer (TNBC). This commonly used type-2 diabetes drug is a plant-based bio-compound known as dimethyl biguanide or metformin and has shown various anticancer properties. One mechanism by which Metformin operates is by inhibiting electron transport chain-complex I in mitochondria, leading to decreased ATP generation and causing energetic stress and reduced energy levels. This disruption hinders natural cellular processes and impedes the growth of tumor cells. The researchers employed electroporation in their experiments by subjecting MDA-MB-231 human TNBC cells to high-intensity, short-duration electrical pulses (EP) in the presence of Metformin. The results showed a significant decrease in cell viability with only 43.45% viability observed compared to 85.20% when using the drug alone at a concentration of 5mM. This suggests that Metformin has potential as an effective treatment option for TNBC. Overall, this study highlights the promising role of Metformin in cancer therapy and underscores the importance of exploring alternative uses for existing medications to combat challenging diseases like triple-negative breast cancer. Further research and clinical trials may be warranted to fully understand the therapeutic benefits of Metformin in treating TNBC and potentially other types of cancer.
- - Metformin, a plant-based bio-compound also known as dimethyl biguanide, has shown various anticancer properties.
- - Metformin inhibits electron transport chain-complex I in mitochondria, leading to decreased ATP generation and causing energetic stress and reduced energy levels.
- - The study used electroporation on TNBC cells with Metformin, resulting in a significant decrease in cell viability compared to using the drug alone.
- - Metformin shows potential as an effective treatment option for triple-negative breast cancer (TNBC).
- - The study highlights the promising role of Metformin in cancer therapy and emphasizes the importance of exploring alternative uses for existing medications to combat challenging diseases like TNBC.
SummaryMetformin is a natural compound that can help fight cancer. It works by stopping the production of energy in cells, making them weaker. When combined with a special technique called electroporation, Metformin can kill cancer cells more effectively. This makes it a good option for treating triple-negative breast cancer. Scientists believe that Metformin could be a valuable tool in fighting difficult diseases like TNBC.
Definitions- Metformin: A plant-based bio-compound used to treat diabetes and showing potential in fighting cancer.
- Anticancer: Properties or abilities that help in preventing or treating cancer.
- ATP: Adenosine triphosphate, which is the molecule that provides energy for cellular processes.
- Electroporation: A method using electric pulses to make cells more permeable and allow substances to enter.
- Triple-negative breast cancer (TNBC): A type of breast cancer that lacks three common receptors known to fuel most breast cancer growth.
Introduction
Breast cancer is the most common type of cancer among women, with an estimated 276,480 new cases and 42,170 deaths in the United States alone in 2020 (1). Among the various subtypes of breast cancer, triple-negative breast cancer (TNBC) is considered to be one of the most aggressive and challenging to treat. TNBC lacks expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2), making it resistant to hormonal therapy and targeted treatments that are effective for other types of breast cancer. This leaves chemotherapy as the primary treatment option for TNBC patients, which can have severe side effects and often leads to drug resistance.
In recent years, researchers have been exploring alternative treatment options for TNBC that could potentially improve patient outcomes while minimizing adverse effects. One such promising avenue is repurposing existing medications for new therapeutic purposes. In their study titled "Electroporation-mediated Metformin for effective anticancer treatment of triple-negative breast cancer cells," authors Praveen Sahu et al. investigated the potential use of Metformin as a treatment option for TNBC.
The Role of Metformin in Cancer Therapy
Metformin is a commonly used medication for type-2 diabetes management. It belongs to a class of drugs called biguanides and has shown various anticancer properties in preclinical studies (2). The bio-compound dimethyl biguanide or metformin is derived from plants and has been used medicinally since ancient times.
One mechanism by which Metformin operates is by inhibiting electron transport chain-complex I in mitochondria, leading to decreased ATP generation and causing energetic stress and reduced energy levels. This disruption hinders natural cellular processes and impedes the growth of tumor cells (3). Additionally, Metformin has been shown to activate AMP-activated protein kinase (AMPK), a key regulator of cellular metabolism, which can inhibit cancer cell growth and promote apoptosis (4).
The Use of Electroporation in the Study
The researchers employed electroporation in their experiments as a means to enhance the delivery of Metformin into TNBC cells. Electroporation is a technique that uses high-intensity, short-duration electrical pulses (EP) to create temporary pores on the cell membrane, allowing for increased uptake of molecules such as drugs or DNA.
In this study, MDA-MB-231 human TNBC cells were subjected to electroporation in the presence of Metformin at varying concentrations. The results showed a significant decrease in cell viability with only 43.45% viability observed compared to 85.20% when using the drug alone at a concentration of 5mM. This suggests that electroporation enhances the effectiveness of Metformin as an anticancer agent for TNBC.
Implications and Future Directions
This study highlights the potential use of Metformin as an effective treatment option for TNBC through its ability to disrupt cellular processes and inhibit tumor growth. The use of electroporation further enhances its efficacy, making it a promising avenue for future research and clinical trials.
One limitation of this study is that it was conducted on only one type of TNBC cell line. Further studies should be conducted on other types and subtypes of breast cancer cells to determine if similar results are observed. Additionally, more research is needed to understand how exactly Metformin affects cancer cells and whether there are any potential side effects or interactions with other treatments.
If proven successful in clinical trials, repurposing Metformin could have significant implications for TNBC patients by providing them with an alternative treatment option that is less toxic than traditional chemotherapy regimens. It could also potentially be used in combination with other therapies to improve treatment outcomes.
Conclusion
In conclusion, the study by Sahu et al. provides valuable insights into the potential use of Metformin as a treatment for TNBC. By utilizing electroporation, the researchers were able to enhance its effectiveness and demonstrate its ability to inhibit cell viability in TNBC cells. This study highlights the importance of exploring alternative uses for existing medications and underscores the promising role of Metformin in cancer therapy. Further research and clinical trials are needed to fully understand its therapeutic benefits and potential as a treatment option for TNBC and potentially other types of cancer.